Back to top
more

Fulgent Genetics (FLGT)

(Delayed Data from NSDQ)

$20.78 USD

20.78
1,028,084

+2.42 (13.18%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $20.77 -0.01 (-0.05%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (71 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +130.43% and +7.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 121.05% and 2.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hims & Hers Health (HIMS) Moves 5.7% Higher: Will This Strength Last?

by Zacks Equity Research

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 133.33% and 1.90%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TruBridge (TBRG) Soars 6.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

TruBridge (TBRG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Schrodinger (SDGR) Moves 14.1% Higher: Will This Strength Last?

by Zacks Equity Research

Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 31.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy

by Zacks Equity Research

Fulgent Genetics (FLGT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

New Strong Buy Stocks for November 22nd

by Zacks Equity Research

SNEX, PKG, APAM, MNDY and FLGT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2024.

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 263.16% and 0.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TruBridge (TBRG) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

TruBridge (TBRG) delivered earnings and revenue surprises of -140.38% and 1.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Fulgent Genetics (FLGT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Hims & Hers Health (HIMS) Soars 10.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Fulgent Genetics (FLGT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Fulgent Genetics (FLGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

How Much Upside is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22%

by Zacks Equity Research

The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 27.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 148.39% and 3.37%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Fulgent Genetics (FLGT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 96.97% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

American Well Corporation (AMWL) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

American Well (AMWL) delivered earnings and revenue surprises of -38.89% and 2.58%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Privia Health (PRVA) Misses Q4 Earnings Estimates

by Zacks Equity Research

Privia Health (PRVA) delivered earnings and revenue surprises of -60% and 3.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Health Catalyst (HCAT) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Health Catalyst (HCAT) delivered earnings and revenue surprises of 300% and 1.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of -21.88% and 31.46%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Olink Holding AB (publ) Sponsored ADR (OLK): Can Its 66.0% Jump Turn into More Strength?

by Zacks Equity Research

Olink Holding AB (publ) Sponsored ADR (OLK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 75.76% and 8.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.